Published in Clin Med Res on August 01, 2005
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A (2008) 1.34
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. PLoS One (2015) 0.77
Spatial resolution and image qualities of Zr-89 on Siemens Biograph TruePoint PET/CT. Cancer Biother Radiopharm (2014) 0.76
Surface properties and cell adhesion onto allylamine-plasma and amine-plasma coated glass coverslips. J Mater Sci Mater Med (2011) 0.75
Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan. Eur J Nucl Med Mol Imaging (2012) 0.75
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.63
Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm (2000) 1.62
Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol (1991) 1.61
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res (1996) 1.47
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res (1996) 1.42
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood (2004) 1.24
Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol (1992) 1.22
Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol (1995) 1.15
Non-Hodgkin's lymphoma. Cancer (1995) 1.08
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma (2009) 1.03
Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res (1999) 0.99
Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res (2003) 0.99
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res (1999) 0.99
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol (2001) 0.95
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.94
Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapy. Cancer Biother Radiopharm (2003) 0.94
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol (2003) 0.91
Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin Cancer Res (1997) 0.85
Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol (2000) 0.84
Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol (1995) 0.83
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res (2003) 0.83
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.83
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood (2004) 0.82
Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol (2003) 0.80
Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs (2002) 0.80
CD20. J Biol Regul Homeost Agents (2002) 0.79
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma (2001) 0.78
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood (2009) 2.46
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol (2010) 2.31
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol (2013) 1.59
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood (2008) 1.42
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leuk Lymphoma (2009) 1.38
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2011) 1.29
Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 1.20
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A (2013) 1.19
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest (2014) 1.16
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol (2007) 1.14
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol (2009) 1.14
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biol Blood Marrow Transplant (2004) 1.07
Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol (2003) 1.07
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus (2006) 1.06
Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant (2007) 1.05
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Biol Blood Marrow Transplant (2010) 1.02
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med (2004) 1.00
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res (2005) 0.95
Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant (2013) 0.93
Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2013) 0.92
Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology (2007) 0.91
Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol (2011) 0.91
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. Int J Radiat Oncol Biol Phys (2010) 0.89
Haploidentical transplantation for leukemia. Curr Oncol Rep (2010) 0.89
Providing personalized prognostic information for adult leukemia survivors. Biol Blood Marrow Transplant (2013) 0.89
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia. Leuk Res (2012) 0.88
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2012) 0.88
Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant (2011) 0.85
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med (2003) 0.85
Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant (2002) 0.85
The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation. J Biol Chem (2002) 0.83
Comparative dosimetry of BEIR VI revisited. Radiat Prot Dosimetry (2004) 0.83
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood (2004) 0.82
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma (2002) 0.82
Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? Chest (2004) 0.81
Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine (2002) 0.81
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma (2008) 0.80
Feasibility of whole-body functional mouse imaging using helical pinhole SPECT. Mol Imaging Biol (2009) 0.80
Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. Br J Haematol (2013) 0.80
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol (2002) 0.79
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol (2007) 0.78
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest (2012) 0.77
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. Proc Natl Acad Sci U S A (2013) 0.77
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol (2012) 0.77
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. Clin Lymphoma Myeloma Leuk (2010) 0.76
New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. Int J Hematol Oncol (2013) 0.75
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma (2008) 0.75
Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol (2004) 0.75
Preliminary production of 211At at the Texas A&M University Cyclotron Institute. Health Phys (2014) 0.75
Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Clin Lymphoma (2003) 0.75
CD52 expression in mantle cell lymphoma. Leuk Lymphoma (2002) 0.75
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. Cancer Invest (2010) 0.75
Radiological safety concerns for the accelerator production of diagnostic and therapeutic radionuclides in a university setting. Health Phys (2012) 0.75
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series. Am J Hematol (2003) 0.75
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. Clin Lymphoma (2004) 0.75
Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. Arch Pathol Lab Med (2006) 0.75